| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | Not to be used |
| Routes | Intravenous infusion |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | 27% (manganese) Negligible (DPDP) |
| Half-life | 20 minutes (manganese) 50 minutes (DPDP) |
| Excretion | Renal and fecal (manganese) Renal (DPDP) |
| Identifiers | |
| ATC code | V08CA05 |
| PubChem | CID 3086672 |
| ChemSpider | 2343239  |
| UNII | N02W67RKJS |
| Chemical data | |
| Formula | C22H28MnN4O14P2 |
| Mol. mass | 689.362 g/mol |
Mangafodipir (sold under the brand name Teslascan as mangafodipir trisodium) is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver. It has two parts, paramagnetic manganese (II) ions and thechelating agent fodipir (dipyridoxyl diphosphate, DPDP). Normal liver tissue absorbs the manganese more than abnormal or cancerous tissue. The manganese shortens the longitudinal relaxation time (T1), making the normal tissue appear brighter in MRIs. This enhanced contrast allows lesions to be more easily identified.
The condensation of pyridoxal 5-phosphate (I) with ethylenediamine (II) in methanol by means of NaOH gives the corresponding diimine (III), which is reduced with hydrogen over Pt/C in methanol/water yielding the expected diamine (IV). The reaction of (IV) with bromoacetic acid (V) by means of NaOH in methanol/water affords the N,N’-diacetic acid derivative (VI), which is finally treated with MnCl2 in water containing NaOH.
References
C22H27MnN4Na3O14P2 
757.33
Trisodium trihydrogen (OC-6-13)-[[N,N¢-1,2-ethanediylbis[N-[[3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycinato]](8-)] manganate(6-).
Trisodium trihydrogen (OC-6-13)-[[N,N¢-ethylenebis[N-[[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridyl]methyl]glycine] 5,5¢-bis(phosphato)](8-)]manganate(6-) [140678-14-4].
Filed under: Uncategorized Tagged: Contrast agent, Diagnostic Aid (MRI Contrast Agent), Mangafodipir, manganese
